News｜J-Pharma Co., Ltd.

Top＞News Lists

News Lists

BREAKFAST MEETING for Prospective Investigators during ASCO~First Step to Start U.S. Phase III Clinical Trial of LAT1 Inhibitor NANVURANLAT for Advanced Biliary Tract Cancer~

Office Relocation Notification

Positive Response Received from U.S. FDA at CMC Type-C Meeting for Novel Anticancer Candidate Drug Nanvuranlat – Important progress toward the start of Phase III Clinical Trial in the U.S.

J-Pharma appoints Keiichi Masuya as Representative Director and Co-CEO, and transits to a new management structure

J-Pharma Raises Maximum ¥5.77 Billion in Funding Accelerates Global Development of LAT1 Inhibitors

Notice of Board of Directors Appointments

Announcement of presentation at the J.P. Morgan, UC Berkeley Healthcare Conference Taipei 2025

Georgetown University Receives Use Patent in Japan for LAT1 Inhibitor to Treat Inflammatory Diseases of the Central Nervous System including Multiple Sclerosis : LAT1 Inhibitor developments initiate new therapeutic possibilities

Announcement of presentation at the J.P. Morgan Healthcare Conference 2025

Tochigi Cancer Center and J-Pharma Enter Into Research Agreement Initiation of Collaborative Research on the Relationship Between the Efficacy of Nanvuranlat and Genetic Mutations in Biliary Tract Cancer Cells

1 2 3 4 5 6 7 8